All In Biotech

Drug Trial Radar · NCT04683185

A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Japanese Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jul 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Dec 28, 2020

Primary completion

Jun 21, 2021

Study completion Jun 21, 2021

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Dec 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending oral doses of E6742 in Japanese healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • E6742Drug

    E6742 tablets.

  • PlaceboDrug

    E6742-matched placebo tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 28 days after the last dose of study drug (approximately Day 35)
  2. Cmax: Maximum Observed Plasma Concentration for E6742 and its Metabolite (ER-001132963) on Day 1Time frame: Day 1: 0-12 hours
  3. tmax: Time at Which the Highest Drug Plasma Concentration Occurs for E6742 and its Metabolite (ER-001132963) on Day 1Time frame: Day 1: 0-12 hours
  4. AUC(0-12h): Area Under the Plasma Concentration-time Curve From Zero Time to 12 Hours Postdose for E6742 and its Metabolite (ER-001132963) on Day 1Time frame: Day 1: 0-12 hours
  5. AUC Metabolite to E6742 Ratio Following Molecular Weight Correction to E6742 Equivalents on Day 1Time frame: Day 1: 0-12 hours
  6. Css,max: Maximum Observed Plasma Concentration at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
  7. tss,max: Time at Which the Highest Drug Plasma Concentration Occurs at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
  8. Css,av: Average Steady State Plasma Concentration for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
  9. AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
  10. AUC(0-12hr): Area Under the Plasma Concentration-time Curve Within a Dosing Interval at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-12 hours
  11. t1/2: Terminal Elimination Phase Half-life for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
  12. CLss/F: Apparent Total Clearance at Steady State for E6742 on Day 7Time frame: Day 7: 0-168 hours
  13. Vss/F: Apparent Volume of Distribution at Steady State for E6742 on Day 7Time frame: Day 7: 0-168 hours
  14. PTF: Peak-trough Fluctuation for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
  15. Accumulation Ratio for Cmax and AUC for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-168 hours
  16. Metabolite to E6742 AUC Ratio Following Molecular Weight Correction to E6742 Equivalents on Day 7Time frame: Day 7: 0-168 hours
  17. AUC(0-12hr)ss: Area Under the Plasma Concentration-time Curve Within a Dosing Interval at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7Time frame: Day 7: 0-12 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eisai Trial Site #1

    Bunkyō-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.